NOVAVAX (NVAX)
$7.14
0.08 (1.12%)
NVAX Stock Quote Delayed 30 Minutes
Novavax Has More Room to Run as the Vaccination Push Carries On
With more overseas deals and its potential to still find success domestically in the booster-shot space, big upside remains for NVAX stock.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
$7.32
Market Cap
1.17B
PE Ratio
-3.60
EPS
-1.9818
Volume (Avg. Vol.)
8.84M
Day's Range
$7.02 - $8.31
52-Week Range
$3.81 - $23.86
Dividend & Yield
N/A (N/A)
NVAX Stock Predictions, Articles, and NOVAVAX News
Novavax Could Rise 56% Once Its Covid-19 Vaccine Is Approved
Novavax is still deeply undervalued. NVAX stock has a good chance of rising to $403.75 once its Covid 19 vaccine rolls out successfully.
How Novavax Stock Can Rally 30% to New Highs
Now is not the time to bet against NVAX stock. The technicals are strong, while Novavax has strong growth estimates for earnings and revenue.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
We're back at it again with one last day of trading this week and we're kicking it off with Friday's biggest pre-market stock movers.
Novavax Stock Is Best Covid Vaccine Name To Speculate On
Novavax used a conventional technology to develop a vaccine, which has slowed development and approval. But there is still time for it to make some big sales.
Novavax Stock Is a Buy Ahead of Potential EU and U.S. Approvals
How high can the share price of pharmaceutical company Novavax go? That's the question investors should be asking themselves as they evaluate the Gaithersburg, Maryland-based company. NVAX stock has been on a tear lately, rising 29% in the past month and up 116% year-to-date. The share price is now flirting with $250.00, begging the question: Does the stock have more runway ahead of it
Government Support Puts Novavax on a Faster Path to Success
While NVAX stock works its way towards all-time highs, traders should prepare for a breakout as Novavax makes headway in vaccine development.
Novavax Stock Is a Steal Here If You Believe It Will Come Through
When it ships an approved Covid-19 vaccine, Novavax is poised for sharp growth for many quarters, as countries grapple to vaccinate people.
Moderna Japan Scare Might Offer a Small Lift to Still-Alive Novavax Stock
Although a recent controversy with competitor MRNA might lift NVAX stock in the near term, it’s not something to depend on.
Novavax Stock Won’t Have Legs in a Reduced-Covid World
There are signs that the pandemic may end soon, and Novavax has had serious supply issues. As a result, NVAX stock looks too risky.
Novavax Looks Like a Good Stock to Trade
For retail traders seeking short-term profits, NVAX stock is looking interesting once again. However, it's not a good long-term investment.
Should Investors Worry a Large Novavax Shareholder Cut Position in Q2?
RA Capital Management is a large Novavax shareholder. It owns 5.1% of NVAX stock. In Q2 2021 it reduced its position slightly. Time to worry?
Novavax Is Selling a Dream, But You Should Live in Reality
The price of NVAX stock reflects hope in the company's Covid-19 vaccine, but hope doesn't change their poor fundamentals.
The Pandemic Is Not Over, And Novavax Is a Strong Contender
Despite the delays in FDA approval, Novavax has made strong strides in the industry, making NVAX stock is a great pharma stock to buy.
Put Novavax Stock on Your Radar for Buying
Maybe not here, but elsewhere and in investors accounts NVAX stock is readying to help in big ways in the coming weeks and months.
Novavax Stock Could Remain a Winner, Despite its ‘Also Ran’ Status
Its vaccine candidate may not have been first in the running. But now with even more ways for NVAX stock to soar from here, now may be the time to buy.
Novavax Is Not a Sure Thing, But It’s Getting Closer
By helping to address the international lack of Covid-19 vaccine access, NVAX stock may be a player in the Covid-19 vaccine race after all.
Buy Novavax In Its Post-Earnings Dip
Novavax's Covid-19 vaccine has strong potential outside the U.S and will generate revenue. This dip is a chance to buy NVAX stock.
The Delta Variant Gives Novavax an Outside Chance of Upside
With the worsening Covid-19 crisis, NVAX stock offers relevance in the international market but you should remain vigilant.
